CPX-351 clinical trials
Also written CPX-351.
How each study uses CPX-351 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CPX-351 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
62 studies that test it; most in 2019 (13); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 13 |
| 2020 | 9 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 55
M.D. Anderson Cancer Center (7) · Jazz Pharmaceuticals (7) · Weill Medical College of Cornell University (4) · Fred Hutchinson Cancer Center (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Children's Oncology Group (3) · National Cancer Institute (NCI) (3) · Case Comprehensive Cancer Center (2)
Often tested with
Tested in the same studies.
Cytarabine (6) · Venetoclax (6) · Gemtuzumab (4) · Azacitidine (4) · Fludarabine (3) · Gilteritinib (3) · Quizartinib (2) · Busulfan (2)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 1 in phase 3
Studies that test CPX-351, phase 3 first.
- Jun 2027Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse GeneticsPhase 3 · University of Ulm
- Dec 2026Phase IB/II of CPX-351 for Relapse Prevention in AMLPhase 1/2 · Georgetown University
- Dec 2026Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaPhase 2 · M.D. Anderson Cancer Center
- Dec 2026Vyxeos® With Clofarabine for Pediatric AMLPhase 1 · Princess Maxima Center for Pediatric Oncology
- Jan 2027Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaPhase 1 · Children's Hospital Medical Center, Cincinnati
- Feb 2027Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AMLPhase 1 · H. Lee Moffitt Cancer Center and Research Institute
- Mar 2027Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Phase 2 · National Cancer Institute (NCI)
- Apr 2027CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLPhase 1 · H. Lee Moffitt Cancer Center and Research Institute
- May 2027Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After InductionPhase 1/2 · Ohio State University Comprehensive Cancer Center
Studies
Open first, then newest update. How each study uses CPX-351 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 63
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)RecruitingPhase 1/2Masonic Cancer Center, University of MinnesotaNCT07008638Written as CPX-351How we know
- CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT03896269Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT05554419Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03629171Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After InductionRecruitingPhase 1/2Ohio State University Comprehensive Cancer CenterNCT04049539Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT04493164Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- Phase IB/II of CPX-351 for Relapse Prevention in AMLRecruitingPhase 1/2Georgetown UniversityNCT04990102Written as CPX-351How we know
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingPhase 1Thomas Jefferson UniversityNCT05627232Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05558124Written as VyxeosHow we know
- Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaRecruitingPhase 1Children's Hospital Medical Center, CincinnatiNCT03826992Written as VyxeosHow we know
- Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AMLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05024552Written as VyxeosHow we know
- Vyxeos® With Clofarabine for Pediatric AMLRecruitingPhase 1Princess Maxima Center for Pediatric OncologyNCT07156435Written as Vyxeos 44 MG / 100 MG Liposome InjectionHow we know
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentNot yet recruitingPhase 2Eastern Cooperative Oncology GroupNCT05628623Written as CPX-351How we know
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT06182592Written as Liposomal cytarabine-daunorubicin for injectionHow we know
- Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04128748Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT05656248Written as CPX-351How we know
- Vyxeos for Induction of Low- or Intermediate-risk.Active, not recruitingPhase 2Shaare Zedek Medical CenterNCT05599360Written as VyxeosHow we know
See all 63 studies that test CPX-351 →
Given beside what is tested · 5 — CPX-351 is usual care or a partner of the new treatment
- A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for InjectionRecruitingNot applicableCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05801835Written as VyxeosHow we know
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04802161Written as Liposome-encapsulated Daunorubicin-CytarabineHow we know
- Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDSWithdrawnPhase 2Uwe PlatzbeckerNCT05829434Written as CPX-351How we know
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 1Jazz PharmaceuticalsNCT04075747Written as CPX-351How we know
- Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.TerminatedPhase 2University of California, San DiegoNCT04425655Written as VyxeosHow we know
As the comparator · 1 — what is tested is compared with CPX-351
Codes
What other systems call CPX-351 · ClinicalTrials.gg INT001046
- MeSH (NLM) C000629812CPX-351One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629812 | CPX-351 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.